跳到主要导航 跳到搜索 跳到主要内容

Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin

  • X. Binghe
  • , Z. Jichang
  • , Z. Aiping
  • Chinese Academy of Medical Sciences

科研成果: 期刊稿件 › 文章 › 同行评审

2 引用 (Scopus)

摘要

Objective: To further evaluate the clinical usefulness of ondensetron(OND, supplied by Qilu Pharmaceutical Company) with modified regime in the prevention of cisplatin (DDP)-induced nausea and vomiting. Methods: A total of 773 patients were enrolled in a multicenter cooperative study. Of them, 330 patients were given iv OND 8 mg once or twice a day and 443 patients were given iv OND 8 mg plus dexamethasone(DXM) 10 mg once a day during the therapeutic period of DDP, followed by OND 4 mg orally twice a day for two days after DDP treatment. Results: Effective control of acute nausea was achieved in 86.7% and 94.8% of the patients receiving OND alone and OND plus DXM, respectively (P<0.001). The mean frequency of vomiting was 0.9 times in OND and 0.4 times in OND plus DXM (P<0.01). Total control of delayed vomiting (day 2~5) was comparable in both groups. Complete inhibition of vomiting (CR rate) was more frequently observed in males than in females. Adverse effects were identical and well tolerated. Conclusion: OND with modified regimen is effective in the control of DDP-induced vomiting. It is more effective when OND and DXM are given than OND given alone.

源语言英语
页(从-至)358-361
页数4
期刊Zhonghua zhong liu za zhi [Chinese journal of oncology]
卷19
期5
出版状态已出版 - 1997

学术指纹

探究 'Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin' 的科研主题。它们共同构成独一无二的学术指纹。

引用此